Acute sinusitis. Acute sinusitis, unspecified
Conditions
Interventions
Intervention 1: In the first group Azitromycin 500 mg tablet was prescribed daily for three days. Intervention 2: In the second group Co-Amoxiclav 625 capsule was prescribed every eight hours for ten
Treatment - Drugs
In the first group Azitromycin 500 mg tablet was prescribed daily for three days.
In the second group Co-Amoxiclav 625 capsule was prescribed every eight hours for ten days.
Sponsors
Shahrekord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Existing at least two major criteria or one major criteria and two minor criteria that lasting at least 7 days and at most 28 days. Major criteria are: facial pain or pressure; facial fullness or congestion; nasal obstruction; purulent rhinorrhea or postnasal discharge; loss of smell; fever. Minor criteria: headache; halitosis; fatigue; toothache; cough; otalgia; fullness of ear. Exclusion criteria: Patients with chronic sinusitis; patients with recurrent sinusitis; patients with anatomical disorders( severe septal deviation; cleft palate; nasal poliposis; patients with chronic disorders (severe hepatic disease; renal disease; heart disease and asthma); women in pregnancy and breast feeding; history of sensitivity to co_ amoxiclav or azitromycin; patients with cilliary dysfunction; cystic fibrosis; congenital or acquired immune deficiency (HIV; diabetes); complications of sinusitis; antibiotic consumption in last one month; patients less than 12 years old or more than 65 years old.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Facial pain. Timepoint: fifth day, tenth day. Method of measurement: clinical evaluation.;Feeling of fullness or congestion of the face. Timepoint: fifth day, tenth day. Method of measurement: clinical evaluation.;Nasal obstruction. Timepoint: fifth day, tenth day. Method of measurement: clinical evaluation.;Purulent discharge of nose or postnasal discharge. Timepoint: fifth day, tenth day. Method of measurement: clinical evaluation.;Loss of smell. Timepoint: fifth day, tenth day. Method of measurement: clinical evaluation.;Fever. Timepoint: fifth day, tenth day. Method of measurement: cheking with termometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Headache. Timepoint: fifth day, tenth day. Method of measurement: history.;Hallitosis. Timepoint: fifth day, tenth day. Method of measurement: history.;Fatigue. Timepoint: fifth day, tenth day. Method of measurement: history.;Toothache. Timepoint: fifth day, tenth day. Method of measurement: history.;Cough. Timepoint: fifth day, tenth day. Method of measurement: history.;Otalgia or feeling of fullness in the ear. Timepoint: fifth day, tenth day. Method of measurement: history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoroush Amani MD
Shahrekord University of Medical Sciences
Outcome results
None listed